Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023

During predominant circulation of SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages (April-June 2023), we found that a second or third booster of Comirnaty bivalent Original/Omicron BA.4-5 mRNA vaccine, versus a first booster received at least 120 days earlier, was effective in preventing severe...

Full description

Saved in:
Bibliographic Details
Published in:Euro surveillance : bulletin européen sur les maladies transmissibles 2023-08, Vol.28 (32)
Main Authors: Fabiani, Massimo, Mateo-Urdiales, Alberto, Sacco, Chiara, Rota, Maria Cristina, Fotakis, Emmanouil Alexandros, Petrone, Daniele, Del Manso, Martina, Siddu, Andrea, Stefanelli, Paola, Bella, Antonino, Riccardo, Flavia, Rezza, Giovanni, Palamara, Anna Teresa, Brusaferro, Silvio, Pezzotti, Patrizio
Format: Article
Language:English
Subjects:
Aged
Antibodies
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines - administration & dosage
Humans
Italy - epidemiology
Middle Aged
mRNA Vaccines
Pandemics
Rapid Communication
RNA, Messenger
SARS-CoV-2 - genetics
Severe acute respiratory syndrome coronavirus 2
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:During predominant circulation of SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages (April-June 2023), we found that a second or third booster of Comirnaty bivalent Original/Omicron BA.4-5 mRNA vaccine, versus a first booster received at least 120 days earlier, was effective in preventing severe COVID-19 for more than 6 months post-administration in persons 60 years and above. In view of autumn 2023 vaccination campaigns, use of bivalent Original/Omicron BA.4-5 mRNA vaccines might be warranted until monovalent COVID-19 vaccines targeting Omicron XBB.1 sublineages become available.
ISSN:1560-7917
1025-496X
1560-7917
DOI:10.2807/1560-7917.ES.2023.28.32.2300397